Navigation Links
NIH funds research to identify Parkinson's biomarkers
Date:2/14/2013

The National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH), awarded a three-year, $900,000 grant to the Center for Biomedical Imaging Statistics at Emory's Rollins School of Public Health. The grant will fund the center's biomarker research in Parkinson's disease to identify non-invasive imaging measures that can detect changes in brain function and biochemistry.

Led by F. DuBois Bowman, PhD, associate professor and director of the Center for Biomedical Imaging Statistics, the team is one of nine research groups funded by NINDS that supports efforts to develop new technologies and tools for biomarker discovery, and data and sharing across the Parkinson's community. The idea is to create a larger study pool to accurately identify biomarkers (changes in the body or brain that can be used to predict, diagnose) in Parkinson's disease.

Bowman's team will develop new statistical tools that identify multiple biomarkers in the brain by observing differences in neural activity or abnormal alterations in brain function and structure.

"Our primary goal is to achieve a better prognosis for patients by identifying neuro-degeneration earlier," says Bowman. "In doing this, we prompt the development of new treatments, accurately identify who is likely to progress to develop Parkinson's, and develop findings that can be used to set up future clinical trials. There are currently no proven biomarkers for this disease."

Parkinson's disease is a movement disorder that affects nearly 1 million people in the United States. The lack of biomarkers for Parkinson's disease has been a major challenge for developing better treatments. Classic signs of the disease include tremors, stiffness and changes in speech and gait. Inside the brain, there is a progressive loss of cells in a motor-controlled region called the substantia nigra and an accumulation of protein-filled structures called Lewy bodies.

According to Bowman, there are no diagnostic tests that confirm Parkinson's disease. Instead, physicians base Parkinson's diagnoses on a combination of medical history, symptoms, neurological and physical examinations, and response to certain medications. Bowman and his team will develop statistical algorithms that will filter through millions of different possible brain measurements to detect changes that indicate neuro-degeneration related to Parkinson's. This will help accurately distinguish groups that are more likely to develop Parkinson's, thus changing what is known about the disease, enabling diagnosis before the classic motor symptoms occur and potentially altering treatments.

The research project has two aims:

1. Imaging-based Biomarkers: Using imaging technology, the team will capture changes in brain activity, structure and pathology related to Parkinson's. A novel aspect of the research will be combining different types of imaging data as well as other biologic information to extract multidimensional Parkinson's disease biomarkers.

2. Utilization of Comprehensive Clinical Database Through a partnership with Kaiser Permanente of Georgia, the researchers will be able to access comprehensive, non-identifiable, patient medical records. They will compare and contrast medical histories, laboratory test results, medications and additional diagnoses to determine a risk-factor profile for Parkinson's.

All nine research groups funded by the NINDS will have access to each group's work through a web-based management system. The researchers will work together to apply their broad clinical and research expertise and samplings to their own research.

"The core of all of our research in the Parkinson's Disease Biomarker Program is to redefine Parkinson's," explains Bowman. "This program allows an avenue for researchers to unite, collaborate and ultimately expedite the advancement of understanding and treatment of Parkinson's disease."


'/>"/>

Contact: Melva Robertson
melva.robertson@emory.edu
404-727-5692
Emory Health Sciences
Source:Eurekalert

Related biology news :

1. Researchers at GW receive federal funds to study the effect earthquakes have on nuclear reactors
2. NIH funds development of tissue chips to help predict drug safety
3. WaterSMART funds $1.7 million for science projects in desert and southern Rockies LCCs
4. EU FET program funds research on 3D neuronal structures mimicking human brain tissue
5. CIRM funds 6 UC San Diego stem cell researchers
6. NASA funds SAO instrument to track North American air pollution
7. Inspired: Canada funds 68 bold, inventive ways to improve health, save lives in developing countries
8. Energy Deptartment funds UW project to turn wasted natural gas into diesel
9. NIH grant funds Boston College research into illnesses afflicting people living with HIV
10. Study by UC Santa Barbara researchers suggests that bacteria communicate by touch
11. Research reveals first evidence of hunting by prehistoric Ohioans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2016)... 2016 Elevay is currently known ... freedom for high net worth professionals seeking travel for ... connected world, there is still no substitute for a ... sealing your deal with a firm handshake. This is ... advantage of citizenship via investment programs like those offered ...
(Date:4/28/2016)... Sweden , April 28, 2016 First ... M (139.9), up 966% compared with the first quarter of 2015 ... profit totaled SEK 589.1 M (loss: 18.8) and the operating margin ... 7.12 (loss: 0.32) Cash flow from operations was SEK ... The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/19/2016)... 2016 The new GEZE SecuLogic ... web-based "all-in-one" system solution for all door components. It ... the door interface with integration authorization management system, and ... The minimal dimensions of the access control and the ... installations offer considerable freedom of design with regard to ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... , ... June 27, 2016 , ... Parallel 6 ... trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module which ... with the physician and clinical trial team. , Using the CONSULT module, patients and ...
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a ... eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research ... by providing practical tips, tools, and strategies for clinical researchers. , “The landscape ...
Breaking Biology Technology: